* Says to get $101,000 deferred rev, $490,000 milestone pay
* Says rev from agreement was 1 pct of overall revenue
Oct 6 DUSA Pharmaceuticals Inc (DUSA.O) sought
to terminate an agreement with a unit of GlaxoSmithKline PLC
(GSK.L) to market and distribute its drug to treat scaly
patches on the skin, in Latin America.
In 2006, DUSA gave Stiefel Laboratories Inc the rights to
distribute, promote and sell its drug Levulan Kerastick in
Latin America for ten years.
With the termination, DUSA will receive deferred revenue
for drug shipments of $101,000 and remaining milestone payments
of $490,000 as of June 30.
The revenue from the agreement in Latin America had been 1
percent of its overall revenue for the first half of 2010, DUSA
said in a regulatory filing.
DUSA's shares, which have gained 2 percent since reporting
better-than-expected quarterly results in August, closed at
$2.51 Tuesday on Nasdaq.
(Reporting by Shravya Jain in Bangalore; Editing by Don